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Abstract Numerous observations suggest a possible connec-
tion between the levels of Mg, Zn, Fe, and Zn and the inci-
dence of depressive symptoms. Depression is two to three
times more common in women than in men. The menopausal
period is extremely conducive to depressive disorders. The
aim of this study was to assess the severity of depressive
symptoms in postmenopausal women depending on the levels
of Mg, Zn, Ca, Cu, and Fe. The study included 198 healthy
pos tmenopausa l women a t t he ave r age age o f
56.26 ± 5.55 years. In the first part of the study, standardized
research tools were used, namely the Primary Care Evaluation
of Mental Disorders (PRIME-MD) and the Beck Depression
Inventory (BDI). The second part involved biochemical anal-
ysis of Mg, Zn, Ca, Cu, and Fe levels in blood serum. The
lowest Cu levels were observed in women without depressive
symptoms (1.07 ± 0.22 mg/l) and the highest in those with
severe depressive symptoms (1.19 ± 0.17 mg/l), (p ≤ 0.05).
The lowest Mg levels were observed in women with depres-
sive symptoms (14.28 ± 2.13 mg/l), and the highest in women
without depressive symptoms (16.30 ± 3.51 mg/l), (p ≤ 0.05).
The average serum Mg levels (15.75 ± 3.23 mg/l) decreased
compared to the reference values (18.77–24 mg/l). What is
striking is a potential relation between the levels of Mg and
Cu and depressiveness. Our results indicate to a higher vul-
nerability to depression in a group of women with lower levels
of Mg and higher levels of Cu.









MHT Menopausal hormone therapy
Introduction
Depression is a mental disorder that is characterized by high
morbidity and mortality. According to estimates of the World
Health Organization, depression is the fourth major cause of
disability among people that depends on years of life. It is
expected that by the year 2020 depression will have occupied
the second place in the classification for several years [1].
Numerous observations suggest a possible connection of the
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level of Mg, Zn, Fe, and Zn and the frequency of occurrence
of depressive symptoms [2].
Depression is a disorder that predominates females (wom-
en suffer two to three times more often than men) [3]. The
menopausal period is extremely conducive to the occurrence
of depressive disorders [4]. This often involves hormonal
changes that result in the end of the reproduction period, ces-
sation of menstruation, vaginal dryness that leads to reduced
libido, dyspareunia, frequent infections in the urogenital sys-
tem, urinary incontinence, and pelvic organ prolapse. In the
perimenopausal period, 20–30 % of women experience de-
pressive disorders that require treatment, and up to 90 % of
women show weaker mood disorders i.e. difficulty concen-
trating, irritability, and emotional lability as a direct result of
hormonal changes [5].
Menopause usually occurs between 47 and 51 years of age,
and the period of life of women after the last menstrual period,
regardless of whether menopause was natural or artificial, is
defined as postmenopause [6]. In Poland, menopause falls on
average on 43–55 years of age, and the average age of
experiencing menopause is 50.8 years [7]. In accordance with
the latest classification proposed by the 2001 Stages of
Reproductive Aging Workshop (STRAW), the postmeno-
pausal period is characterized by an increase in the FSH level
and a decrease in the oestradiol level. Changes in the levels of
these hormones are particularly visible in the first two years
after the last menstrual period, and then the hormone levels
stabilize. The postmenopausal period begins after 12 months
without menstruation [8].
The average lifespan for women has considerably in-
creased since the beginning of the last century, causing that
currently approximately 30 % of women’s lives is spent in the
postmenopausal period. Therefore, women’s health problems
associated with menopause and ovarian steroid deficiency
have become an important issue for public health. More and
more often researchers focus on looking for biological factors
that affect depressiveness as in this case micronutrients may
be important.
Mg is a bivalent intracellular cation which acts as a coen-
zyme or an activator for approximately 300 enzymatic sys-
tems, especially for enzymes involved in the transfer of phos-
phate groups and energy changes in a cell [9]. The regulating
effect of Mg exerted on N-methyl-D-aspartate (NMDA) chan-
nels makes it an important factor in the treatment of depres-
sion [10]. Prolonged Mg deficiency can lead to the develop-
ment of atherosclerosis, cardiovascular diseases, and metabol-
ic disorders. Mg deficiency can cause endocrine disorders i.e.
hyperthyroidism, primary aldosteronism, hyperparathyroid-
ism, and neurological disorders such as paraesthesia, in-
creased muscle contraction, convulsions, and loss of con-
sciousness [11]; it also promotes development of mental dis-
orders [12]. Hypomagnesaemia occurs in situations of chronic
stress, alcohol abuse, diet rich in carbohydrates and fats, or
containing increased amounts of Ca, as well as situations of
increased physical activity and elimination diets (especially
when combined with the use of laxatives) [13].
Zn is an essential micronutrient necessary for normal cel-
lular metabolism in the human body. It plays a fundamental
role in a wide range of biochemical processes. Zn is an im-
portant modulator of functioning of the central nervous system
[14]. Zn deficiency in humans is relatively rare. It was de-
scribed in cases of emotional stress, and such diseases as giar-
diasis, diarrhoea, acute pancreatitis, and chronic renal failure.
Prolonged Zn deficiency is manifested, among others, in neu-
ropsychiatric disorders such as apathy, depression, and lack of
concentration [15].
Zn and Mg deficiency in women can significantly reduce
their quality of life, causing palpitations, trembling hands and
feet, paraesthesia, impaired immune system, symptoms of
dryness and roughness of the skin, hair loss, apathy, depres-
sion, impaired concentration, and impaired vision, hearing,
taste, and smell [9].
Ca is a bivalent cation that is predominantly accumulated in
bone tissue (i.e. in 99 %). Some authors believe that the main
cause of instability of the atherosclerotic plaque is the deposi-
tion of Ca deposits in place of inflammation [16].
Hypocalcaemia manifests itself in fragility of hair and nails,
and it can also lead to mood disorders, irritability, depression,
and increased sleepiness. In the course of hypocalcaemia,
there may be dizziness and even loss of consciousness [17].
Another microelement important for the functioning of the
human body is Cu, which mainly accumulates in the liver,
muscles, the skeletal system, and the brain. If the concentra-
tion of Cu in blood serum is too high it results in damage to the
kidneys, liver, and coronary arteries. Cu deficiency can man-
ifest itself in disorders of the circulatory system, the nervous
system, the digestive system, and it can cause loss of hair
pigmentation [18].
Fe is mainly a component of haemoglobin, myoglobin, and
some enzymes (cytochromes, catalase, peroxidase). It is de-
livered with food and absorbed in the small intestine; later, it is
excreted in faeces with scaly cells [19]. In the human body, it
transports oxygen through haemoglobin. The most common
cause of Fe deficiency is poor diet, malabsorption, blood loss,
and chronic inflammation. Due to limiting of aerobic changes
in muscles and advantage of anaerobic changes due to the low
concentration of Fe, its deficiency is manifested mainly in
weakness, and a decrease in the overall efficiency of the hu-
man body. There are also skin lesions in the form of tongue
inflammation, lip sores in the corners of the mouth, itching,
fragility, and brittle hair and nails. Moreover, a decrease in
body temperature and appetite can be observed. Some authors
associate the restless leg syndrome with Fe deficiency [20,
21].
Excess of Fe is due to excessive storage of this micronutri-
ent in the course of hemochromatosis, also known as brown
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diabetes. This leads to multiple organ complications. Fe accu-
mulates in the liver, pancreas, myocardium, and the skinmain-
ly in the form of haemosiderin [22].
The aim of the study was to:
1. Assess the concentration of Mg, Zn, Ca, Cu, and Fe in
blood serum in postmenopausal women.
2. Assess the severity of depressiveness depending on the
concentration of Mg, Zn, Ca, Cu, and Fe in postmeno-
pausal women.
Material and Methods
The study included 198 healthy postmenopausal women, res-
idents of the West Pomeranian Province in Poland. Women
were chosen according to the following criteria: postmeno-
pausal period confirmed by absence of menstruation for at
least a year, no menopausal hormone therapy (MHT) in med-
ical history, no current psychiatric treatment, no tumours, lack
of thyroid diseases and diabetes, lack of addictions (alcohol
and cigarettes), correct blood pressure parameters, no dietary
supplements and any drugs.
The research was approved by the [hidden for blind re-
view], No. KB-0012/154/12.
The first part of the research was carried out using the
diagnostic survey method. The following standardized re-
search tools were used:
– PRIME-MD questionnaire to exclude women with axis I
mental disorders according to ICD-10 [20].
– Beck’s depression scale—general physical and mental
state self-study for determining the severity of
depressiveness. The following standards were used: no
depression (0–11), mild depression (12–26), moderate
depression (27–49), and heavy depression (50–63).
The study sample was divided according to the severity of
depression (no depression, mild, moderate, and heavy depres-
sion) and according to the presence or absence of depression.
The second part of the research included biochemical stud-
ies of the concentration of bio-elements: Mg, Zn, Ca, Cu, and
Fe in blood serum.
After obtaining consent to participate in the study from
each patient, 5 ml of blood was taken to determine the con-
centration of the following microelements in serum: Mg, Ca,
Cu, Fe, and Zn. Blood samples were collected with the
Vacutainer on an empty stomach (at least 8 h after the last
meal). Biological material was then centrifuged (10 min,
4000 rpm/min) and storage in –20 °C. After being thawed,
blood serum was mixed and diluted with distilled water.
Serum samples were diluted 1:2 to determine the
concentrations of Zn, Cu, and Fe and 30:3 to determine the
concentrations of Ca andMg. Zn, Cu and Fe, Ca andMgwere
determined using the atomic absorption spectrometry and an
atomic absorption spectrometer—PU 9100X by Philips.
Concentrations were read using the designated patterns of
the Titrisol® curve by Merck. Working wavelength for Zn—
213.9 nm, for Fe—248.3 nm, and for Cu—354.8 nm, for
Ca—422.7 nm, and for Mg—285.2 nm. When determining
Ca and Mg, the lanthanum chloride solution was used as the
ionization buffer. Determinations were made using the
acetylene-oxygen flame.
Results of the control studies were assessed twice accord-
ing to the adopted 2SD rule byWestgard, which says that if in
the control study the result of reproducibility is outside the
2SD range, it is necessary to make the determination in the
control sample one more time. If the result is within the range
of expected values it is assumed that the deviation in the first
study was random in nature, and the results of the whole series
are correct. However, if the second analysis demonstrates a
value that is beyond the 2SD range once again, it must be
assumed that the whole series of determinations associated
with this sample is also encumbered with an error, so the
results cannot be considered reliable (the series rejection prin-
ciple). In such cases, the cause of an error was identified, and
then the control and the series of determinations were
repeated.
The results of the control were documented and written in
Levey-Jenings’ control charts. Laboratory tests were carried
out in the Department of Chemistry and Biochemistry at the
Pomeranian Medical University in Szczecin.
The standard laboratory reference was the concentration
range of Mg—18.77–24 mg/l, Fe—0.5–1.7 mg/l, Ca—81–
105 mg/l, Zn—0.75–1.3 mg/l, and Cu—0.97–1.17 mg/l.
Statistical analysis was performed using Statistica PL. The
study sample was characterized by quantitative variables,
using minimum and maximum values, arithmetic mean, and
standard deviation. The differences were assessed bymeans of
the Mann-WhitneyU test and the Student’s t test. Correlations
between two variables were analysed using Spearman’s rank
correlation coefficient. The level of significance was set at
p ≤ 0.05.
Characteristics of the Study Group
The average age of the studied women was 56.26 ± 5.55, the
median was 55 years, the youngest respondent was 42 years
old, and the oldest was 70 years old. More than half of the
studied women had secondary education—56 % and higher
education—32 %. Most women were residents of cities, in-
cluding 62 % of cities over 100,000 residents, and 23 % of
smaller towns with population of 10,000–100.000 people.
58 Małgorzata et al.
Married women accounted for 69 % of the respondents, pro-
fessionally active women—65 % of the respondents.
Results
Data analysis showed statistically significant differences in the
concentrations of Mg and Cu. The average concentration of Cu
in the entire group of the studied women amounted to
1.10 ± 0.22 mg/l and was within the range accepted as the norm
(0.97–1.17 mg/l). The lowest concentration of Cu was observed
in womenwithout symptoms of depressiveness (1.07 ± 0.22mg/
l) and the highest in women with severe depressiveness
(1.19 ± 0.17 mg/l), and these differences were statistically sig-
nificant (p ≤ 0.05) (Fig. 1). The lowest concentration of Mg was
observed in women with symptoms of severe depressiveness
(14.28 ± 2.13mg/l) and the highest in womenwithout symptoms
of depressiveness (16.30 ± 3.51mg/l), and these differenceswere
statistically significant (p ≤ 0.05) (Fig. 1). For the average con-
centration of Mg (15.75 ± 3.23 mg/l) in blood serum of the
studied postmenopausal women, there was deficiency in this
micronutrient relative to the standard (18.77–24 mg/l).
The lowest concentration of Fe (1.02 ± 0.33 mg) was ob-
served in women who had no symptoms of depressiveness,
and in women with mild symptoms of depressiveness
(1.07 ± 0.42 mg). The highest average concentration of Fe
(1.27 ± 0.55 mg) in the study group was found in women with
severe symptoms of depressiveness. The average concentra-
tion of this element in the entire group of the studied postmen-
opausal women amounted to 1.06 ± 0.36 mg/l and was within
the range accepted as the norm (0.5–1.7 mg/l). In the case of
Zn, the lowest average concentration was found in women
with severe depressiveness (0.61 ± 0.07 mg/l), and the highest
in women with mild depressiveness (0.74 ± 0.17mg/l), and no
symptoms of depressiveness (0.71 ± 0.40 mg/l). The average
concentration of Zn in the entire group of postmenopausal
women was 0.70 ± 0.33 mg/l and was lower than the norm
for this micronutrient (0.75–1.3 mg/l). The highest concentra-
tion of Ca was observed in women without symptoms of
depressiveness (73.25 ± 12.04 mg/l) and the lowest in women
who showed severe symptoms of depressiveness
(67.13 ± 11.65 mg/l). The average concentration of this mi-
cronutrient in the entire group of the studied women was
72.59 ± 11.78 mg/l and was lower than the value that is com-
monly accepted as the norm (81–105 mg/l) (Table 1).
The analysis of data resulting from the assessment of con-
centration of micronutrients in postmenopausal women was
made taking into account women whose self-assessment
showed symptoms of depressiveness (n = 70) (mild, medium,
and severe), and women who were not diagnosed with such
symptoms (n = 128). The concentration of Mg was signifi-
cantly higher in women without symptoms of depressiveness
than in women who had experienced these symptoms.
Moreover, statistically significant differences (p ≤ 0.05) for
the concentration of Cu were observed; lower concentration
occurred in women without symptoms of depressiveness and
higher in women diagnosed with symptoms of depressiveness
(Table 2).
The analysis of data showed a statistically significant
(p < 0.05) negative correlation between the concentration of
Mg and depressiveness and a statistically significant (p ≤ 0.05)
positive correlation between the concentration of Cu and
depressiveness (Table 3).
Discussion
Analysing the effect of various concentrations of
micronutrients on severity of depressiveness and anxiety
among the studied women, a negative correlation between
the concentration of Mg in blood serum and severity of
depressiveness in the surveyed women was demonstrated
Fig. 1 The concentration of Mg and Cu in blood serum of postmenopausal women, and the presence or lack of depression
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(p < 0.05) and a significant positive correlation between the
concentration of Cu and depressiveness in the studied popu-
lation of female patients (p < 0.05). For concentrations of Fe,
Ca, and Zn in blood, the occurrence of depressiveness in the
surveyed women no significant correlations were shown
(p > 0.05).
Reports concerning the concentration of Mg in blood se-
rum in the course of depression are not clear. Research carried
out by Frizel et al. showed that the concentration of Mg in
patients with depression was substantially reduced, and an
effective electroconvulsive therapy or tryptophan-based ther-
apy correlate with normalization of the concentration of this
element in plasma of the respondents [23]. In research by
Zięba et al., it was shown that there was a slight reduction in
the concentration of Mg in blood serum of patients with de-
pression compared to the control group. In this case, the
severity of depression assessed using Hamilton’s scale did
not correlate with the concentration of Mg [24]. In the publi-
cation of Widmer et al., higher levels of Mg in blood serum of
patients with unipolar depression compared to healthy volun-
teers were observed, and there was no relation between the
concentration of the micronutrient and the mental state of the
respondents [25]. Fitzpatrick et al. indicate that Mg deficiency
in postmenopausal women can cause or exacerbate depressive
symptoms [4]. Research that assesses the level of Mg in blood
serum made among 650 people diagnosed with depression in
Iraq showed that the mean total serum magnesium was
2.1 ± 0.26 mg/dl. In the study group consisting of both men
(30 %) and women (70 %) , i t was shown tha t
hypomagnesaemia occurred in 13.7 %, hypermagnesaemia
in 8.3 %, and the sub-optimal magnesium levels were present
in 26.5 %. There was a significant relationship between
Table 1 The average
concentration of Mg, Zn, Ca, Cu,
and Fe in blood serum of women
and the severity of depressiveness
Severity of depressiveness n X
− SD Min-Max Me Q1−Q3
Mg (mg/l)
No depression 128 16.30 ± 3.51 8.69–27.17 15.50 13.99–18.33
Mild 39 14.64 ± 2.35 10.50–21.61 14.54 12.62–15.35
Moderate 21 15.10 ± 2.42 10.20–20.20 14.54 13.84–16.56
Heavy 10 14.28 ± 2.13 10.71–17.27 14.29 13.03–16.36
Total 198 15.75 ± 323 8.69–27.17 15.15 13.73–17.57
Zn (mg/l)
No depression 128 0.71 ± 0.40 0.43–4.82 0.64 0.57–0.74
Mild 39 0.74 ± 0.17 0.46–1.12 0.72 0.61–0.85
Moderate 21 0.63 ± 0.13 0.46–0.98 0.63 0.54–0.68
Heavy 10 0.61 ± 0.07 0.53–0.72 0.60 0.55–0.66
Total 198 0.70 ± 0.33 0.43–4.82 0.65 0.57–0.77
Ca (mg/l)
No depression 128 73.25 ± 12.04 41.10–109.28 74.03 65.35–81.76
Mild 39 72.52 ± 12.18 52.21–110.59 70.39 64.34–82.72
Moderate 21 71.30 ± 9.19 50.70–87.06 73.12 66.66–75.04
Heavy 10 67.13 ± 11.65 48.38–85.14 70.24 54.64–75.14
Total 198 72.59 ± 11.78 41.10–110.59 73.42 64.74–80.90
Cu (mg/l)
No depression 128 1.07 ± 0.22 0.46–1.71 1.04 0.92–1.25
Mild 39 1.12 ± 0.22 0.46–1.60 1.13 1.05–1.24
Moderate 21 1.16 ± 0.24 0.78–1.58 1.09 0.99–1.35
Heavy 10 1.19 ± 0.17 0.90–1.50 1.13 1.11–1.30
Total 198 1.10 ± 0.22 0.46–1.71 1.08 0.95–1.26
Fe (mg/l)
No depression 128 1.02 ± 0.33 0.29–1.78 1.00 0.79–1.29
Mild 39 1.07 ± 0.42 0.34–2.04 1.07 0.76–1.27
Moderate 21 1.13 ± 0.24 0.82–1.81 1.08 1.00–1.20
Heavy 10 1.27 ± 0.55 0.38–2.21 1.10 0.98–1.57
Total 198 1.06 ± 0.36 0.29–2.21 1.05 0.84–1.28
n the number of surveyed women, X
− SD average deviation, Min-Max. minimum and maximum values, Me
median, Q1 lower quartile, Q3 higher quartile
60 Małgorzata et al.
depression and the level of Mg in blood serum (p = 0.02).
Hypomagnesaemia influenced the severity of depression in a
significant manner, which strongly suggests an important role
of Mg in pathogenesis of depression [10].
McNair et al. reported an increased excretion of Mg by
kidneys in postmenopausal women. It was found that the use
of MHT reduces excretion of Mg in urine [26]. This relation-
ship, however, was not confirmed by Bednarek-Tupikowska.
She analysed 120 women, divided into a group using MHT
and a group free of the therapy, and did not observe any sig-
nificant differences in the concentrations of Mg in blood se-
rum between these two groups of women [27].
The available literature on occurrence of depressiveness in
postmenopausal women shows that there are significant dif-
ferences in the frequency and severity of depressive symptoms
between menopausal women undergoing the hormone thera-
py, and those who did not apply it [28]. Janicka et al. studied
60 postmenopausal women who used the hormone therapy,
and 30 patients who did not use MHT. To assess symptoms of
depression, Beck’s depression scale was used. The overall rate
of depression was significantly higher in women who did not
use the hormone therapy compared to womenwho usedMHT.
In the group of women not using MHT symptoms of
depressiveness are more frequently diagnosed, and they are
more severe than in the case of patients who use it [29]. The
specificity of depressive disorders in the menopausal period is
based on similarity of symptoms to those which occur as a
result of oestrogen deficiency. In both cases, there is insomnia,
mood swings, anxiety, irritability, difficulty concentrating,
memory issues, and loss of libido. The clinical picture in the
menopausal period includes symptoms of concomitant dis-
eases and a higher level of psychomotor agitation and anxiety
[30]. There are attempts to define laboratory markers of de-
pression among which there are hormonal markers (such as
the dexamethasone suppression test, thyrotropin or fenflur-
amine stimulation test), immunological, serum lipids, as well
as blood cell markers, amino acids, monoamines, neurodegen-
eration markers, and some micronutrients.
Among micronutrients, particular attention is paid to the
role of Zn, Mg, and Cu as essential modulators of glutamate
transmission that are connected with etiopathogenesis of de-
pression [30–32]. Literature indicates that in many research
studies carried out among patients diagnosed with depression
hypocalcaemia, hypomagnesaemia, and/or lack of Zn and Fe
were found [33].
Hansen et al.’s reports signalled that in patients with
refractory depression the concentration of Zn in blood se-
rum is significantly reduced [34]. McLoughlin and Hodge
presented research which showed that patients diagnosed
with depression were characterized by a significant reduc-
tion in the concentration of Zn in blood serum, and that the
regression of symptoms of depression is accompanied by
an increase in the concentration of this micronutrient [35].
Also, other researchers, such as Maes et al., Nowak et al.,
and Schlegel-Zawadzka et al., provided evidence for a neg-
ative correlation between the severity of depression and the
concentration of Zn in plasma [36–38]. Siwek et al. studied
30 patients aged 18–55 diagnosed with recurrent depression
treated for 12 weeks with imipramine in a daily dose of
100–200 mg and a control group of 25 volunteers. It was
shown that during the period of acute symptoms of depres-
sion the concentration of Zn was significantly lower than in
healthy volunteers. In that research, there was no significant
correlation between the concentration of Zn and severity of
Table 2 The average
concentration of Mg, Zn, Ca, Cu,
and Fe in blood serum of
postmenopausal women with no
symptoms of depressiveness and







− SD X− SD
Mg (mg/l) 16.31 ± 3.51 14.73 ± 2.33 3.37876t ≤0.05
Zn (mg/l) 0.71 ± 0.40 0.69 ± 0.15 0.48195t >0.05
Ca (mg/l) 73.25 ± 12.04 71.39 ± 11.28 1.286800Z >0.05
Cu (mg/l) 1.07 ± 0.22 1.14 ± 0.22 −2.42699Z ≤0.05
Fe (mg/l) 1.03 ± 0.33 1.12 ± 0.40 −1.20896Z >0.05
X
− SD average deviation, t/ZMann-Whitney’s test probability coefficient
Table 3 The analysis of correlation between severity of depressiveness
and the concentration of Mg, Zn, Ca, Cu, and Fe in blood serum of the
studied women
Severity of depressiveness
Micronutrients n R t (N-2) p
Mg (mg/l) 198 −0.212301 −3.04154 <0.05
Zn (mg/l) 198 −0.017664 −0.24734 >0.05
Ca (mg/l) 198 −0.102752 −1.44618 >0.05
Cu (mg/l) 198 0.179406 2.55310 <0.05
Fe (mg/l) 198 0.102543 1.44321 >0.05
R Spearman’s rank correlation coefficient, t (N-2) statistics of test that
verifies the significance of the R correlation coefficient, p significance
level calculated for R
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depression measured using Beck’s depression inventory or
Hamilton’s depression scale. In patients who met the
criteria of remission, the concentration of Zn in blood se-
rum was statistically significantly higher. The authors con-
cluded that the concentration of Zn in plasma is a marker
that indicates presence of the state of depression but does
not reflect severity of symptoms of depression [30].
Research conducted by Nowak shows that Zn homeostasis
in the human body plays an important role in the mecha-
nism of treatment with antidepressants [14].
Prospective cohort research shows that taking high doses of
Zn in a diet is associated with a decrease in incidence of
depression. This relation concerned both women and men
[39]. In a randomized blinded and placebo-controlled study,
it was shown that dietary supplements containing Zn had in-
fluence on improvement of mood, reduction of anger, and
hostility [40].
In research by Jurczak et al. conducted on a group of 323
postmenopausal women, of which 152 applied MHT and 171
were free of the therapy, it was demonstrated that women
using MHT presented high levels of Mg and Zn in blood
serum compared to the control group [41].
In our research, we demonstrated a statistically significant
(p < 0.05) positive correlation between the concentration of
Cu in blood and severity of depression in analysed patients.
The lower concentration of Cu occurred in women without
symptoms of depressiveness (1.07 ± 0.22 mg/l) and higher
(1.14 ± 0.22 mg/l) in women diagnosed with depressiveness.
Similar results were obtained byManser et al. [42] and Narang
et al. [43]. In both cases, the concentration of Cu was studied
among patients diagnosed with a history of depression by
comparing them with healthy volunteers. Patients with symp-
toms of depression presented a statistically significant high
concentration of this element compared to the control group.
It was also shown that an effective antidepressant therapy
results in a significant reduction in the concentration of Cu
in blood serum of the respondents [43]. Similar results were
also obtained by Schlegel-Zawadzka et al. [44], who studied
19 patients diagnosed with unipolar depression and a group of
16 healthy volunteers. The average concentration of Cu in
patients with depression was higher by 21 % than in the con-
trol group. In this research, no correlation was obtained be-
tween severity of depression measured using Hamilton’s de-
pression scale and the concentration of Cu in blood serum of
patients.
Different results were obtained byMaes et al. [45] compar-
ing the concentration of Cu in blood serum of 31 patients
diagnosed with major depression, and 15 healthy volunteers.
Before starting the treatment of patients diagnosed with de-
pression, the concentration of Cu showed no significant dif-
ferences. However, a statistically significant decrease in the
concentration of Cu among respondents with depression dur-
ing effective treatment was observed.
Conclusions
1. The postmenopausal women analysed in this study had
decreased levels of Zn, Mg, and Ca compared to the ref-
erence values.
2. What is striking is a potential relation between the levels
of Mg and Cu and depressiveness. Our results indicate to
a higher vulnerability to depression in a group of women
with lower levels of Mg and higher levels of Cu.
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